A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 45/06 (2006.01) A61P 5/02 (2006.01) A61P 5/08 (2006.01)
Patent
CA 2604381
Disclosed is a method for attenuating the effects of growth hormone (GH) in a subject. The method comprises the administration of both a GH antagonist and a somatostatin agonist to said subject, simultaneously or separately, continuously or periodically. In one preferred embodiment of the method an extended release somatostatin agonist composition is administered monthly (such as ocreotide LAR/SANDOSTATIN LAR or Lanreoride autogel/SOMATULINE AUTOGEL) , and a conventional non-extended release GH antagonist composition is administered weekly (such as pegvisomant) .
L'invention concerne un procédé qui permet d'atténuer les effets de l'hormone de croissance ("growth hormone" ou GH) chez un sujet. Le procédé consiste à administrer à la fois un antagoniste de l'hormone de croissance et un antagoniste de la somatostatine audit sujet, de manière simultanée ou séparément, de manière continue ou périodique. Dans un mode de réalisation préféré du procédé, une composition d'un agoniste de la somatostatine à libération prolongée est administrée mensuellement, et une composition d'un agoniste de l'hormone de croissance classique, à libération non prolongée, est administrée sur une base hebdomadaire.
Erasmus University Medical Centre Rotterdam
Smart & Biggar
LandOfFree
Use of growth hormone antagonist and somatostatin agonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of growth hormone antagonist and somatostatin agonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of growth hormone antagonist and somatostatin agonist will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1499628